TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PanGenomic Health, Inc. Class A ( (TSE:NARA) ) just unveiled an update.
PanGenomic Health Inc. has expanded its investor relations agreement with Fairfax Partners Inc. to enhance its communications infrastructure and marketing services. Under the new agreement, PanGenomic will pay Fairfax a monthly fee and allocate funds for digital marketing to boost brand visibility and commercial growth, indicating a strategic move to strengthen its market presence.
Spark’s Take on TSE:NARA Stock
According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.
The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.
To see Spark’s full report on TSE:NARA stock, click here.
More about PanGenomic Health, Inc. Class A
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company is registered as a British Columbia benefit company and focuses on promoting alternative health solutions tailored to individual health profiles.
Average Trading Volume: 83,552
Technical Sentiment Signal: Buy
Current Market Cap: C$30.9M
See more insights into NARA stock on TipRanks’ Stock Analysis page.